Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

KRAS mutation analysis of single circulating tumor cells from patients with metastatic colorectal cancer.

Kondo Y, Hayashi K, Kawakami K, Miwa Y, Hayashi H, Yamamoto M.

BMC Cancer. 2017 May 3;17(1):311. doi: 10.1186/s12885-017-3305-6.

2.

Feasibility of multiplexed gene mutation detection in plasma samples of colorectal cancer patients by mass spectrometric genotyping.

Shin SJ, Chun SM, Kim TI, Kim YJ, Choi HJ, Jang SJ, Kim J.

PLoS One. 2017 May 1;12(5):e0176340. doi: 10.1371/journal.pone.0176340. eCollection 2017.

3.

Advances in Biomarkers: Going Beyond the Carcinoembryonic Antigen.

Lopez NE, Peterson CY.

Clin Colon Rectal Surg. 2016 Sep;29(3):196-204. doi: 10.1055/s-0036-1584289. Review.

PMID:
27582644
4.

Clinical Implications and Future Perspectives of Circulating Tumor Cells and Biomarkers in Clinical Outcomes of Colorectal Cancer.

Huang MY, Tsai HL, Huang JJ, Wang JY.

Transl Oncol. 2016 Aug;9(4):340-7. doi: 10.1016/j.tranon.2016.06.006. Review.

5.

Development of a deregulating microRNA panel for the detection of early relapse in postoperative colorectal cancer patients.

Yang IP, Tsai HL, Miao ZF, Huang CW, Kuo CH, Wu JY, Wang WM, Juo SH, Wang JY.

J Transl Med. 2016 Apr 29;14(1):108. doi: 10.1186/s12967-016-0856-2.

6.

Utility of KRAS mutation detection using circulating cell-free DNA from patients with colorectal cancer.

Yamada T, Iwai T, Takahashi G, Kan H, Koizumi M, Matsuda A, Shinji S, Yamagishi A, Yokoyama Y, Tatsuguchi A, Kawagoe T, Kitano S, Nakayama M, Matsumoto S, Uchida E.

Cancer Sci. 2016 Jul;107(7):936-43. doi: 10.1111/cas.12959. Epub 2016 Jun 13.

7.

Detection of KRAS mutations in circulating tumor cells from patients with metastatic colorectal cancer.

Buim ME, Fanelli MF, Souza VS, Romero J, Abdallah EA, Mello CA, Alves V, Ocea LM, Mingues NB, Barbosa PN, Tyng CJ, Chojniak R, Chinen LT.

Cancer Biol Ther. 2015;16(9):1289-95. doi: 10.1080/15384047.2015.1070991. Epub 2015 Aug 7. Erratum in: Cancer Biol Ther. 2015;16(11):1689.

8.

Comparison of genetic and epigenetic alterations of primary tumors and matched plasma samples in patients with colorectal cancer.

Danese E, Minicozzi AM, Benati M, Montagnana M, Paviati E, Salvagno GL, Lima-Oliveira G, Gusella M, Pasini F, Lippi G, Guidi GC.

PLoS One. 2015 May 6;10(5):e0126417. doi: 10.1371/journal.pone.0126417. eCollection 2015.

9.

Circulating free DNA as biomarker and source for mutation detection in metastatic colorectal cancer.

Spindler KL, Pallisgaard N, Andersen RF, Brandslund I, Jakobsen A.

PLoS One. 2015 Apr 13;10(4):e0108247. doi: 10.1371/journal.pone.0108247. eCollection 2015.

10.

May CTC technologies promote better cancer management?

Pesta M, Kulda V, Narsanska A, Fichtl J, Topolcan O.

EPMA J. 2015 Jan 22;6(1):1. doi: 10.1186/s13167-014-0023-x. eCollection 2015.

11.

Relationship between circulating tumor cells and tumor response in colorectal cancer patients treated with chemotherapy: a meta-analysis.

Huang X, Gao P, Song Y, Sun J, Chen X, Zhao J, Liu J, Xu H, Wang Z.

BMC Cancer. 2014 Dec 18;14:976. doi: 10.1186/1471-2407-14-976.

12.

Detection of activated KRAS from cancer patient peripheral blood using a weighted enzymatic chip array.

Huang MY, Liu HC, Yen LC, Chang JY, Huang JJ, Wang JY, Hsiao CP, Lin SR.

J Transl Med. 2014 May 26;12:147. doi: 10.1186/1479-5876-12-147.

13.

Circulating tumor cells: exploring intratumor heterogeneity of colorectal cancer.

Raimondi C, Nicolazzo C, Gradilone A, Giannini G, De Falco E, Chimenti I, Varriale E, Hauch S, Plappert L, Cortesi E, Gazzaniga P.

Cancer Biol Ther. 2014 May;15(5):496-503. doi: 10.4161/cbt.28020. Epub 2014 Feb 12.

14.

The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer.

Huang CW, Tsai HL, Chen YT, Huang CM, Ma CJ, Lu CY, Kuo CH, Wu DC, Chai CY, Wang JY.

BMC Cancer. 2013 Dec 13;13:599. doi: 10.1186/1471-2407-13-599.

15.

In vitro validation of an ultra-sensitive scanning fluorescence microscope for analysis of circulating tumor cells.

Hillig T, Nygaard AB, Nekiunaite L, Klingelhöfer J, Sölétormos G.

APMIS. 2014 Jun;122(6):545-51. doi: 10.1111/apm.12183. Epub 2013 Oct 29.

16.

High-performance size-based microdevice for the detection of circulating tumor cells from peripheral blood in rectal cancer patients.

Sun W, Jia C, Huang T, Sheng W, Li G, Zhang H, Jing F, Jin Q, Zhao J, Li G, Zhang Z.

PLoS One. 2013 Sep 16;8(9):e75865. doi: 10.1371/journal.pone.0075865. eCollection 2013.

17.

KRAS Testing: A Tool for the Implementation of Personalized Medicine.

Shackelford RE, Whitling NA, McNab P, Japa S, Coppola D.

Genes Cancer. 2012 Jul;3(7-8):459-66. doi: 10.1177/1947601912460547.

18.

Comparison of KRAS/BRAF mutations between primary tumors and serum in colorectal cancer: Biological and clinical implications.

Pu X, Pan Z, Huang Y, Tian Y, Guo H, Wu L, He X, Chen X, Zhang S, Lin T.

Oncol Lett. 2013 Jan;5(1):249-254. Epub 2012 Oct 10.

19.

KRAS mutation testing in metastatic colorectal cancer.

Tan C, Du X.

World J Gastroenterol. 2012 Oct 7;18(37):5171-80. doi: 10.3748/wjg.v18.i37.5171. Review.

20.

Detection of circulating tumor cells: Clinical relevance of a novel metastatic tumor marker.

Ren C, Han C, Wang D, Zhao X, Jin G, Shen H.

Exp Ther Med. 2011 May;2(3):385-391. Epub 2011 Mar 21.

Supplemental Content

Support Center